Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.

about

Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.

Item

http://www.wikidata.org/entity/Q55383330

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@en

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@nl

type

Item

label

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@en

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@nl

prefLabel

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@en

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@nl

P1476

Natural compound Oblongifolin ...... ulating Src/MAPK/ERK pathways.

@en

P2093

Hongsheng Tan

http://www.w3.org/2001/XMLSchema#string

Hongxi Xu

http://www.w3.org/2001/XMLSchema#string

Shuangfan Cai

http://www.w3.org/2001/XMLSchema#string

Xiaoqiong Chen

http://www.w3.org/2001/XMLSchema#string

Yang Li

http://www.w3.org/2001/XMLSchema#string

Yingyi Li

http://www.w3.org/2001/XMLSchema#string

Zhen Wang

http://www.w3.org/2001/XMLSchema#string

Zhichao Xi

http://www.w3.org/2001/XMLSchema#string

P2860

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway

Pancreatic cancer

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.

Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.

MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.

Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?

c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Ubiquitin-mediated degradation of active Src tyrosine kinase

Src continues aging: current and future clinical directions.

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.

P304

538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41419-018-0574-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chen Liang

Yuanzhi Lao

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29749405

http://www.w3.org/2001/XMLSchema#string

P932

5970202

http://www.w3.org/2001/XMLSchema#string